Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 201–300 of 1,002
Guindon, J., Lai, Y., Takacs, S. M., Bradshaw, H. B., & Hohmann, A. G. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.013 · Cited by 160
“) was previously validated to increase accumulation of anandamide but not 2-AG in rat brain [62].”
BackgroundPan, B., Wang, W., Zhong, P., Blankman, J. L., Cravatt, B. F., & Liu, Q.-S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2075-11.2011 · Cited by 146
“Pharmacological and genetic studies indicate that FAAH and MAGL are key regulators of eCB-dependent signaling and behavior (Cravatt et al., 2001; Kathuria et al., 2003; Long et al., 2009; Chanda et al., 2010; Schlosburg et al., 2010).”
BackgroundA role for cannabinoid CB1 receptors in mood and anxiety disorders
Witkin, J. M., Tzavara, E. T., & Nomikos, G. G. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00005 · Cited by 180
“…dopaminergic and cholinergic primary projection neurons (Lu et al., 1999; Ong and Mackie, 1999; Hermann et al., 2002), GABAergic interneurons (Katona et al., 1999; Tsou et al., 1999), and in postsynaptic processes (Rodriguez et al., 2001), places CB1 receptors within key vantage points to…”
BackgroundFatty acid amide hydrolase deficiency limits early pregnancy events
Wang, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28621 · Cited by 156
“The evidence that anandamide is beneficial to alleviating pain, cancer, neurodegeneration, and anxiety has heightened interest and efforts to develop FAAH inhibitors as novel therapeutic agents for treating these conditions (25, 49–51).”
Bidirectional cannabinoid modulation of social behavior in adolescent rats
Trezza, V., & Vanderschuren, L. J. M. J. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1025-3 · Cited by 159
“To investigate the physiological role of the endocannabinoid system in the modulation of social behavior, we used the indirect cannabinoid agonist URB597, which inhibits fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anandamide (Kathuria et al. 2003).”
BackgroundMethodAnalgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain
Jhaveri, M. D., Richardson, D., Kendall, D. A., Barrett, D. A., & Chapman, V. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3326-06.2006 · Cited by 159
“URB597 has been shown to produce a rapid and sustained ( 6 h) inhibition of FAAH activity in the brain and to increase levels of AEA and other related fatty acids (Kathuria et al., 2003; Fegley et al., 2005; Hohmann et al., 2005; Makara et al., 2005).”
BackgroundResultInfluentialHaller, J., Barna, I., Barsvari, B., Gyimesi Pelczer, K., Yasar, S., Panlilio, L. V., & Goldberg, S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1494-7 · Cited by 159
“…Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript to decrease anxiety, there were sometimes discrepant findings regarding the effective doses (Cippitelli et al. 2008; Hill et al. 2007; Kathuria et al. 2003; Patel and Hillard 2006; Scherma et al. 2008; Moreira et al. 2008).”
InfluentialBluett, R. J., Gamble-George, J. C., Hermanson, D. J., Hartley, N. D., Marnett, L. J., & Patel, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.53 · Cited by 157
Evaluation of NHS Carbamates as a Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors
Niphakis, M. J., Cognetta, A. B., Chang, J. W., Buczynski, M. W., Parsons, L. H., Byrne, F., Burston, J. J., Chapman, V., & Cravatt, B. F. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400116z · Cited by 157
Review article: endocannabinoids and their receptors in the enteric nervous system
Duncan, M., Davison, J. S., & Sharkey, K. A. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02648.x · Cited by 174
Shonesy, B. C., Bluett, R. J., Ramikie, T. S., Báldi, R., Hermanson, D. J., Kingsley, P. J., Marnett, L. J., Winder, D. G., Colbran, R. J., & Patel, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.001 · Cited by 155
“…of exogenous cannabinoids (Patel and Hillard, 2006; Rey et al., 2012) and by pharmacological or genetic augmentation of eCB levels (Hermanson et al., 2013; Kathuria et al., 2003; Moreira et al., 2008; Patel and Hillard, 2006; Rossi et al., 2010; Sciolino et al., 2011; Sumislawski et al., 2011).”
InfluentialStructure-guided inhibitor design for human FAAH by interspecies active site conversion
Mileni, M., Johnson, D. S., Wang, Z., Everdeen, D. S., Liimatta, M., Pabst, B., Bhattacharya, K., Nugent, R. A., Kamtekar, S., Cravatt, B. F., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806121105 · Cited by 153
“, trif luoromethyl ketones (23, 24), f luorophosphonates (25), -ketoheterocycles (26), carbamates (8, 27)].”
Scherma, M., Medalie, J., Fratta, W., Vadivel, S. K., Makriyannis, A., Piomelli, D., Mikics, É., Haller, J., Yaşar, S., Tanda, G., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.011 · Cited by 171
“…as URB597 (cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester) have recently been developed which can be used to magnify and prolong the effects of both endogenously released and exogenously administered anandamide (Kathuria et al., 2003; Lichtman et al., 2004; Mor et al., 2004; Fegley et al., 2005).”
BackgroundSelf-citationA new strategy to block tumor growth by inhibiting endocannabinoid inactivation
Bifulco, M., Laezza, C., Valenti, M., Ligresti, A., Portella, G., & Marzo, V. D. (2004) · The FASEB Journal · doi:10.1096/fj.04-1754fje · Cited by 157
“Interestingly, arvanil, a metabolically stable, mixed inhibitor of endocannabinoid cellular reuptake and partial CB1 agonist, which is inactive on FAAH, also significantly inhibited tumor Page 4 of 14 (page number not for citation purposes) growth (down to ~60% of vehicle treated tumors at a 1.0 mg/kg dose, intratumor…”
BackgroundInfluentialWang, X., Sarris, K., Kage, K., Zhang, D., Brown, S. P., Kolasa, T., Surowy, C. S., El-Kouhen, O. F., Muchmore, S. W., Brioni, J. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801042a · Cited by 165
The endocannabinoid system: An emotional buffer in the modulation of memory function
Morena, M., & Campolongo, P. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.12.010 · Cited by 166
“The indirect cannabinoid receptor agonists URB597 and AM404, which increase AEA levels in the synaptic cleft, have been reported to exert both anxiolytic-and antidepressant-like effects in rodents (Bortolato et al., 2006; Gobbi et al., 2005; Kathuria et al., 2003).”
BackgroundAnxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray
Moreira, F. A., de Aguiar, D. C., & Guimarães, F. S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.013 · Cited by 160
Estrogen recruits the endocannabinoid system to modulate emotionality
Hill, M. N., Karacabeyli, E., & Gorzalka, B. B. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.02.003 · Cited by 156
“More specifically, inhibition of the primary enzyme involved in AEA metabolism, fatty acid amide hydrolase (FAAH), reduces anxiety on several rodent indices such as ultrasonic vocalizations and open arm avoidance in the EPM (Kathuria et al., 2003; Patel and Hillard, 2006).”
BackgroundResultInfluentialThe Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids
Marzo, V. D., Bisogno, T., & PETROCELLIS, L. D. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-26573-2_5 · Cited by 177
Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses
Viveros, M.-P., Marco, E.-M., Llorente, R., & López-Gallardo, M. (2007) · Neural Plasticity · doi:10.1155/2007/52908 · Cited by 141
“In turn, AM404 that is considered as an inhibitor of endocannabinoids uptake exerted an action that was more similar to that elicited by direct agonists, with low doses producing anxiolytic effects and the highest dose having no effect [98].”
BackgroundIzawa, Y., Zheng, C., & Stahl, S. S. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209457 · Cited by 164
Morena, M., Roozendaal, B., Trezza, V., Ratano, P., Peloso, A., Hauer, D., Atsak, P., Trabace, L., Cuomo, V., McGaugh, J. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420285111 · Cited by 158
“Our findings indicate that the FAAH inhibitor URB597, which increases endogenous AEA levels in the synaptic cleft (28), enhanced 48-h retention when infused into the BLA, hippocampus, or mPFC after training.”
BackgroundSelf-citationFurther evidence for the existence of a specific process for the membrane transport of anandamide
Ligresti, A., Morera, E., van der Stelt, M., Monory, K., Lutz, B., Ortar, G., & Marzo, V. D. (2004) · Biochemical Journal · doi:10.1042/bj20031812 · Cited by 149
Evidence for Bidirectional Endocannabinoid Transport across Cell Membranes
Chicca, A., Marazzi, J., Nicolussi, S., & Gertsch, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.373241 · Cited by 169
“FAAH inhibition leads to higher intracellular levels of AEA compared with vehicletreated cells, as reported for URB597 (56, 74, 75), whereas blocking the cell membrane transport leads to a reduced cellular penetration of AEA, as reported for several inhibitors (19– 21).”
BackgroundEndocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
Jhaveri, M. D., Richardson, D., & Chapman, V (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707433 · Cited by 144
“Functional effects of inhibition of FAAH in models of pain A number of studies have shown that FAAH is the predominant enzyme responsible for the hydrolysis of AEA (Cravatt et al., 2001; Kathuria et al., 2003; Lichtman et al., 2004; Cravatt and Lichtman, 2004a; Fegley et al., 2005).”
BackgroundHegde, V. L., Hegde, S., Cravatt, B. F., Hofseth, L. J., Nagarkatti, M., & Nagarkatti, P. S. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047035 · Cited by 154
“URB532 has been shown to be a very potent and selective inhibitor of FAAH (Kathuria et al., 2003).”
BackgroundEndocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 159
Melancia, F., Schiavi, S., Servadio, M., Cartocci, V., Campolongo, P., Palmery, M., Pallottini, V., & Trezza, V. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14435 · Cited by 145
“injection, the enzyme hydrolysing anandamide, fatty acid amide hydrolase, is maximally inhibited and anandamide levels are significantly increased (Gobbi et al., 2005; Kathuria et al., 2003).”
BackgroundSelf-citationAlhouayek, M., & Muccioli, G. G. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.07.009 · Cited by 162
Cannabinoid Tolerance and Dependence
Lichtman, A. H., & Martin, B. R. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_24 · Cited by 154
Lomazzo, E., Bîndilă, L., Remmers, F., Lerner, R., Schwitter, C., Hoheisel, U., & Lutz, B. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.198 · Cited by 154
Lafenêtre, P., Chaouloff, F., & Marsicano, G. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.006 · Cited by 152
Servadio, M., Melancia, F., Manduca, A., di Masi, A., Schiavi, S., Cartocci, V, Pallottini, V, Campolongo, P., Ascenzi, P., & Trezza, V (2016) · Translational Psychiatry · doi:10.1038/tp.2016.182 · Cited by 139
Anandamide transport: A critical review
Glaser, S. T., Kaczocha, M., & Deutsch, D. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.007 · Cited by 144
Szabo, B., Urbanski, M. J., Bisogno, T., Marzo, V. D., Mendiguren, A., Baer, W. U., & Freiman, I. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.119362 · Cited by 140
“In the presence of URB597 (5 × 10−7 m), the inhibition by anandamide developed faster and it was also more pronounced.”
BackgroundInfluentialMcLaughlin, R. J., Hill, M. N., & Gorzalka, B. B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.006 · Cited by 157
Alexander, J. P., & Cravatt, B. F. (2006) · Journal of the American Chemical Society · doi:10.1021/ja062999h · Cited by 140
Rubino, T., Sala, M., Viganò, D., Braida, D., Castiglioni, C., Limonta, V., Guidali, C., Realini, N., & Parolaro, D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301330 · Cited by 143
“Recent data obtained with pharmacological agents that enhance the endocannabinoid tone join this complex picture suggesting that anandamide too has a role in the regulation of anxiety states (Bortolato et al, 2006; Kathuria et al, 2003).”
BackgroundBraida, D., Capurro, V., Zani, A., Rubino, T., Viganò, D., Parolaro, D., & Sala, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00230.x · Cited by 160
“%) was able to induce an anxiolytic effect, evaluated in the elevated plus maze, when URB 597 (0.01 mg·rat-1) was injected into the prefrontal cortex (Rubino et al., 2008) or given i.p. (0.3 mg·kg-1) (Kathuria et al., 2003; Gobbi et al., 2005).”
BackgroundInfluentialNovel bioactive metabolites of dipyrone (metamizol)
Rogosch, T., Sinning, C., Podlewski, A., Watzer, B., Schlosburg, J. E., Lichtman, A. H., Cascio, M. G., Bisogno, T., Marzo, V. D., Nüsing, R. M., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.028 · Cited by 145
Trezza, V., & Vanderschuren, L. J. M. J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.03.001 · Cited by 152
“URB597 has been shown to have positive effects in rodent models used to screen anxiolytic and antidepressant drugs (Gobbi et al., 2005; Hill et al., 2007; Kathuria et al., 2003; Moreira et al., 2007; Patel and Hillard, 2006; Naidu et al., 2007).”
BackgroundShould peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?
Kunos, G., Osei-Hyiaman, D., Bátkai, S., Sharkey, K. A., & Makriyannis, A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.001 · Cited by 137
“Although CB1 receptors responsible for the addictive nature of cannabis and those implicated in analgesia, antinausea or anxiolytic effects might be located at distinct sites in the brain [3], they are pharmacologically indistinguishable.”
BackgroundBambico, F. R., Cassano, T., Domínguez-López, S., Katz, N., Walker, C. D., Piomelli, D., & Gobbi, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.80 · Cited by 154
“…mechanism of antidepressants and anxiolytics, these drugs elicit identical effects detected in a wide range of behavioral tests and animal models for depression and anxiety (Bambico et al, 2007, 2009a; Bortolato et al, 2007; Gobbi et al, 2005; Hill and Gorzalka, 2005; Kathuria et al, 2003).”
BackgroundSelf-citationScherma, M., Panlilio, L. V., Fadda, P., Fattore, L., Gamaleddin, I., Foll, B. L., Justinová, Z., Mikics, É., Haller, J., Medalie, J., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142224 · Cited by 147
“…a selective inhibitor of FAAH, URB597, to magnify and prolong the effects of only one of the endocannabinoid signals, the AEA signal, when and where AEA is synthesized and released on demand in activated synapses (Kathuria et al., 2003; Fegley et al., 2005; Pertwee, 2005; Piomelli et al., 2006).”
BackgroundMethodInfluentialSelf-citationMcKinney, M. K., & Cravatt, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303922200 · Cited by 138
Zhong, P., Wang, W., Pan, B., Liu, X., Zhang, Z., Long, J. Z., Zhang, H., Cravatt, B. F., & Liu, Q.-S. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.24 · Cited by 142
“Pharmacological blockade or genetic knockout of FAAH produces anxiolytic- and antidepressant-like effects primarily via CB1 receptors (Bambico et al, 2009; Bambico et al, 2007; Bortolato et al, 2007; Gobbi et al, 2005; Kathuria et al, 2003; Patel and Hillard, 2006).”
BackgroundThe complications of promiscuity: endocannabinoid action and metabolism
Alexander, S. P. H., & Kendall, D. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707456 · Cited by 133
“Recently, high concentrations (X10 mM) of URB597 have been described to activate TRPA1, a cation channel expressed in sensory neurones (Niforatos et al., 2007) and to activate PPARg in cells lacking native FAAH1 expression (Dionisi et al., 2007).”
BackgroundInfluentialDisruption of CB1 receptor signaling impairs extinction of spatial memory in mice
Varvel, S. A., Anum, E. A., & Lichtman, A. H. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2121-2 · Cited by 145
“…that it may be possible to facilitate extinction under certain conditions by administering cannabinoid agonists (Parker et al. 2004) or blocking fatty acid amide hydrolase, which results in elevated levels of endogenous anandamide (Cravatt et al. 2001; Kathuria et al. 2003; Lichtman et al. 2004).”
BackgroundFatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In Vivo
Capasso, R., Matias, I., Lutz, B., Borrelli, F., Capasso, F., Marsicano, G., Mascolo, N., Petrosino, S., Monory, K., Valenti, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.018 · Cited by 144
Snider, N. T., Walker, V. J., & Hollenberg, P. F. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.001081 · Cited by 152
“In addition to neuroprotection, FAAH inhibitors also produce anxiolysis (Kathuria et al., 2003).”
BackgroundInfluentialThe discovery and development of inhibitors of fatty acid amide hydrolase (FAAH)
Otrubova, K., Ezzili, C., & Boger, D. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.096 · Cited by 149
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
van Egmond, N., Straub, V. M., & van der Stelt, M. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-112741 · Cited by 122
Chang, J. W., Cognetta, A. B., Niphakis, M. J., & Cravatt, B. F. (2013) · ACS Chemical Biology · doi:10.1021/cb400261h · Cited by 150
“A primary strategy for developing irreversible serine hydrolase inhibitors exploits the intrinsic reactivity of active-site serine nucleophiles, a unifying feature of this enzyme class, by designing complementary electrophiles, such as activated lactams,(23, 24) lactones,(25) carbamates(26, 27) and ureas.”
BackgroundMazzola, C., Medalie, J., Scherma, M., Panlilio, L. V., Solinas, M., Tanda, G., Drago, F., Cadet, J. L., Goldberg, S. R., & Yaşar, S. (2009) · Learning & Memory · doi:10.1101/lm.1145209 · Cited by 152
Lee, S.-H., Ledri, M., Toth, B., Marchionni, I., Henstridge, C. M., Dudok, B., Kenesei, K., Barna, L., Szabo, S. I., Renkecz, T., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4112-14.2015 · Cited by 133
“For comparison purposes, the pretreatment effects of another widely used FAAH inhibitor, URB597 [3 (aminocarbonyl)[1,1 -biphenyl]-3-yl)-cyclohexylcarbamate] (1 M; Kathuria et al., 2003), on endocannabinoid levels were also measured.”
MethodCota, D. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.764 · Cited by 124
“Several inhibitors of anandamide cellular re-uptake or transport and of anandamide hydrolysis have also been identified, presenting multiple pharmacologic opportunities to affect the ECS [55,56].”
BackgroundWalter, L., Dinh, T., & Stella, N. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2419-04.2004 · Cited by 127
“, 1999a , b ; Kathuria et al .”
Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice
Steiner, M. A., Wanisch, K., Monory, K., Marsicano, G., Borroni, E., Bächli, H., Holsboer, F., Lutz, B., & Wotjak, C. T. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500466 · Cited by 144
Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy
Khasabova, I. A., Khasabov, S., Paz, J., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0403-12.2012 · Cited by 129
“Because URB597 binds to FAAH with high affinity and slow dissociation kinetics, leading to its description as an “irreversible” FAAH inhibitor (Kathuria et al., 2003), we determined whether the anti-hyperalgesic effect of URB597 in this experimental paradigm was due to the activation of CB1R by an endogenous ligand.”
BackgroundHabib, A. M., Okorokov, A. L., Hill, M. N., Brás, J., Lee, M.-C., Li, S., Gossage, S. J., van Drimmelen, M., Morena, M., Houlden, H., et al. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.02.019 · Cited by 139
Biosynthesis, degradation and pharmacological importance of the fatty acid amides
Farrell, E. K., & Merkler, D. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.006 · Cited by 142
Luchicchi, A., & Pistis, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8299-0 · Cited by 143
More surprises lying ahead. The endocannabinoids keep us guessing
Piomelli, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.026 · Cited by 128
“Consistent with this view, genetic or pharmacological interventions that interrupt FAAH activity cause a profound enhancement in anandamide-mediated signaling at CB1 cannabinoid receptors (Cravatt et al, 2001; Kathuria et al., 2003), whereas blockade of NAAA or AC exerts no such effect (Realini et al.”
Self-citationIgnatowska‐Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J., Abdullah, R. A., Tao, Q., O' Neal, S. T., Walentiny, D. M., Wiley, J. L., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12298 · Cited by 128
“, 2012), and acute thermal nociception (Kathuria et al., 2003; Lichtman et al., 2004b).”
BackgroundTsuboi, K., Okamoto, Y., Ikematsu, N., Inoue, M., Shimizu, Y., Uyama, T., Wang, J., Deutsch, D. G., Burns, M. P., Ulloa, N. M., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.009 · Cited by 135
Li, G. L., Winter, H. R., Arends, R., Jay, G. W., Le, V., Young, T., & Huggins, J. P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04137.x · Cited by 127
Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation
Hermanson, D. J., Hartley, N. D., Gamble-George, J., Brown, N., Shonesy, B. C., Kingsley, P. J., Colbran, R. J., Reese, J., Marnett, L. J., & Patel, S. (2013) · Nature Neuroscience · doi:10.1038/nn.3480 · Cited by 126
“Since the anxiolytic effects of FAAH inhibition are mediated via AEA acting on CB 1 cannabinoid receptors 22,40 , we next tested the role of CB 1 receptors in the anxiolytic-like behavioral effects of LM-4131 in the open field arena.”
InfluentialSiegmund, S. V., Qian, T., de Minicis, S., Harvey‐White, J., Kunos, G., Vinod, K. Y., Hungund, B., & Schwabe, R. F. (2007) · The FASEB Journal · doi:10.1096/fj.06-7717com · Cited by 122
T-Type Calcium Channel Inhibition Underlies the Analgesic Effects of the Endogenous Lipoamino Acids
Barbara, G., Alloui, A., Nargeot, J., Lory, P., Eschalier, A., Bourinet, E., & Chemin, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2919-09.2009 · Cited by 125
“2 (inhibition at 3 M was 86 1%, n 7, and was 88 2%, n 5, in the presence of PMSF and URB597, respectively) (see supplemental Fig.”
BackgroundA Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis
Hernández‐Torres, G., Cipriano, M., Hedén, E., Björklund, E., Canales, Á., Zian, D., Feliú, A., Mecha, M., Guaza, C., Fowler, C. J., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201407807 · Cited by 125
Karanian, D. A., Brown, Q. B., Makriyannis, A., Kosten, T. A., & Bahr, B. A. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2347-05.2005 · Cited by 134
“As with transport inhibition, disrupting FAAH activity through genetic and pharmacological means also enhances endocannabinoid signaling (Cravatt et al., 2001; Kathuria et al., 2003).”
Sharkey, K. A., Cristino, L., Oland, L. D., Van Sickle, M. D., Starowicz, K., Pittman, Q. J., Guglielmotti, V., Davison, J. S., & Di Marzo, V. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05521.x · Cited by 120
“In the next study, the endocannabinoid reuptake inhibitor, VDM11 (2 mg ⁄ kg, De Petrocellis et al., 2000; Tocris) and the inhibitor of anandamide hydrolysis, URB597 (5 mg ⁄ kg, Kathuria et al., 2003; Axorra) were administered 15 min before M6G.”
BackgroundMethodModulation of the serotonin system by endocannabinoid signaling
Haj‐Dahmane, S., & Shen, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.016 · Cited by 138
“On the other hand, pharmacological enhancement of eCB signaling via the blockade of eCB metabolism and/or uptake reduces stress-related behaviors and facilitates the extinction of conditioned fear-responses (Kathuria et al., 2003).”
Patel, S., Carrier, E. J., Ho, W. ‐. V., Rademacher, D. J., Cunningham, S., Reddy, D. S., Falck, J. R., Cravatt, B. F., & Hillard, C. J. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400377-jlr200 · Cited by 124
“URB532 was synthesized as described previously (12).”
BackgroundMethodInfluentialThe Endocannabinoid System and Extinction Learning
Lutz, B. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-8004-x · Cited by 132
“Genetic Studies To date, the only way to genetically enhance the endocannabinoid signaling was achieved by the generation of mice deficient for FAAH, leading to 10 to 15 times increased basal levels of anandamide [27].”
BackgroundInfluentialSystemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex
Oropeza, V. C., Page, M. E., & Bockstaele, E. J. V. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.036 · Cited by 136
Harnessing the anti-inflammatory potential of palmitoylethanolamide
Alhouayek, M., & Muccioli, G. G. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.007 · Cited by 128
Sagar, D. R., Staniaszek, L. E., Okine, B. N., Woodhams, S., Norris, L. M., Pearson, R. G., Garle, M. J., Alexander, S. P. H., Bennett, A. J., Barrett, D. A., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27698 · Cited by 119
Lötsch, J., Weyer-Menkhoff, I., & Tegeder, I. (2017) · European Journal of Pain · doi:10.1002/ejp.1148 · Cited by 126
Pacher, P., Mukhopadhyay, P., Rajesh, M., Godlewski, G., Bátkai, S., & Kunos, G. (2008) · Hypertension · doi:10.1161/hypertensionaha.105.063651 · Cited by 139
Wei, D., Dinh, D., Lee, D., Li, D., Anguren, A., Moreno-Sanz, G., Gall, C. M., & Piomelli, D. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0008 · Cited by 122
“is particularly important in light of the known roles of endocannabinoids in stress modulation.(19,30,40,41) In our case, we found that the prosocial action of ananda-”
BackgroundSelf-citationJhaveri, M. D., Richardson, D., Robinson, I., Garle, M. J., Patel, A., Sun, Y., Sagar, D. R., Bennett, A. J., Alexander, S. P. H., Kendall, D. A., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.018 · Cited by 122
Hermanson, D. J., Gamble-George, J. C., Marnett, L. J., & Patel, S. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.006 · Cited by 121
“AEA is primarily degraded by fatty acid amide hydrolase (FAAH), and pharmacological inhibition of FAAH causes robust increases in brain AEA concentrations [9, 10].”
BackgroundMethodForget, B., Coen, K. M., & Foll, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1569-5 · Cited by 129
“3– 1 mg/kg) have been chosen based on previous studies (Kathuria et al. 2003; Scherma et al. 2008; Solinas et al. 2005, 2006).”
BackgroundMethodResultInfluentialMuntoni, A. L., Pillolla, G., Melis, M., Perra, S., Gessa, G. L., & Pistis, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04759.x · Cited by 120
“…this possibility is further supported by the latest evidence showing that URB597, a selective inhibitor of the endocannabinoid anandamide degradation (Kathuria et al., 2003), is able to enhance the spontaneous firing rate of LC NA cells in a SR141617Asensitive manner (Gobbi et al., 2005).”
BackgroundInfluentialGanon-Elazar, E., & Akirav, I. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.204 · Cited by 120
Schlosburg, J. E., Carlson, B. L. A., Ramesh, D., Abdullah, R. A., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9110-7 · Cited by 119
“In the present study, we employed FAAH (−/−) mice as well as URB597 (34) and JZL184 (33) to investigate whether increasing endogenous cannabinoid levels can ameliorate”
The role of prefrontal cortex CB1 receptors in the modulation of fear memory
Lin, H.-C., Mao, S.-C., Su, C.-L., & Gean, P.-W. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn075 · Cited by 119
Endocannabinoids and neurodegenerative diseases
Micale, V., Mazzola, C., & Drago, F. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.008 · Cited by 130
Hill, M. N., & Gorzalka, B. B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.06.069 · Cited by 119
Marzo, V. D., Bisogno, T., & PETROCELLIS, L. D. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.05.014 · Cited by 123
Endocannabinoid Signaling in the Control of Social Behavior
Don, W., Allsop, S. A., Tye, K. M., & Piomelli, D. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.005 · Cited by 129
“Moreover, microinjection of the FAAH inhibitor URB597, which stops anandamide degradation and increases its levels [50], into either of these two brain regions, enhanced social play [49,51].”
Self-citationRole of the endocannabinoid system in drug addiction
Manzanares, J., Cabañero, D., Puente, N., García‐Gutiérrez, M. S., Grandes, P., & Maldonado, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.013 · Cited by 127
Interleukin-1β Causes Anxiety by Interacting with the Endocannabinoid System
Rossi, S., Sacchetti, L., Napolitano, F., Chiara, V. D., Motta, C., Studer, V., Musella, A., Barbieri, F. R., Bari, M., Bernardi, G., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1515-12.2012 · Cited by 126
“…disorders, and magnification of endocannabinoid signaling has antidepressant and antianxiety actions in humans (Hariri et al., 2009) and in rodents (Kathuria et al., 2003; Gobbi et al., 2005; Patel and Hillard, 2006; Micale et al., 2009; Rossi et al., Received March 28, 2012; revised Aug. 7, 2012;…”
Tyndale, R. F., Payne, J. I., Gerber, A. L., & Sipe, J. C. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30491 · Cited by 117
“, 2004] leading to increased endogenous anandamide levels that have been shown to reduce anxiety in mammals [Kathuria et al., 2003; Patel and Hillard, 2006] and supported by effects of exogenous cannabinoids on anxiety [Rutkowska et al.”
BackgroundTartaglione, A. M., Schiavi, S., Calamandrei, G., & Trezza, V. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.024 · Cited by 130
Braida, D., Limonta, V., Malabarba, L., Zani, A., & Sala, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.038 · Cited by 128
Tuo, W., Leleu‐Chavain, N., Spencer, J., Sansook, S., Millet, R., & Chavatte, P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00538 · Cited by 126
Naidu, P. S., Booker, L., Cravatt, B. F., & Lichtman, A. H. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143487 · Cited by 122
Pavón, F. J., Bilbao, A., Hernández‐Folgado, L., Cippitelli, A., Jagerovic, N., Abellán, G., Rodríguez-Franco, M. I., Serrano, A., Macías, M., de Heras, R. G., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.029 · Cited by 124
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.